Esr1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer

被引：0
|
作者：
Zhang, Qiang
Jiao, Jianhua
D'Amico, Paolo
Davis, Andrew A.
Qin, Weijun
Gerratana, Lorenzo
Jacob, Saya L.
Zhang, Youbin
Donahue, Jeannine
Qiang, Wenan
Shah, Ami N.
Flaum, Lisa
Gradishar, William
Platanias, Leonidas C.
Cristofanilli, Massimo
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-01-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-01-08
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Study of ESR1 Expression and Estrogen Receptor Signaling Pathway in Breast Cancer Patients
    Long, Bing
    Watson, Linden
    Dowell, Angeline
    Walker, Kimberly
    Rao, Arundhati
    MODERN PATHOLOGY, 2015, 28 : 53A - 53A
  • [42] The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas*
    Moreira-Dinzey, Jennifer
    Zhan, Haiying
    Rozenblit, Mariya
    Krishnamurti, Uma
    Harigopal, Malini
    Zhong, Minghao
    Liang, Yuanxin
    HUMAN PATHOLOGY, 2023, 137 : 56 - 62
  • [43] Targeting wild type and ESR1 mutations as neoantigens in hormone receptor positive breast cancer
    Gautam, Namrata
    Albert, Gabriella
    Synder, Colin
    Czerniecki, Brian
    CANCER RESEARCH, 2024, 84 (03)
  • [44] Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
    Spoerke, Jill M.
    Gendreau, Steven
    Walter, Kimberly
    Qiu, Jiaheng
    Wilson, Timothy R.
    Savage, Heidi
    Aimi, Junko
    Derynck, Mika K.
    Chen, Meng
    Chan, Iris T.
    Amler, Lukas C.
    Hampton, Garret M.
    Johnston, Stephen
    Krop, Ian
    Schmid, Peter
    Lackner, Mark R.
    NATURE COMMUNICATIONS, 2016, 7
  • [45] Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
    Jill M. Spoerke
    Steven Gendreau
    Kimberly Walter
    Jiaheng Qiu
    Timothy R. Wilson
    Heidi Savage
    Junko Aimi
    Mika K. Derynck
    Meng Chen
    Iris T. Chan
    Lukas C. Amler
    Garret M. Hampton
    Stephen Johnston
    Ian Krop
    Peter Schmid
    Mark R. Lackner
    Nature Communications, 7
  • [46] Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer
    Busonero, Claudia
    Leone, Stefano
    Bartoloni, Stefania
    Acconcia, Filippo
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2019, 480 : 107 - 121
  • [47] Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Aktas, Bahriye
    Mueller, Volkmar
    Tewes, Mitra
    Zeitz, Julia
    Kasimir-Bauer, Sabine
    Loehberg, Christian R.
    Rack, Brigitte
    Schneeweiss, Andreas
    Fehm, Tanja
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 356 - 360
  • [48] Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
    Niu, Jiaxin
    Andres, Grant
    Kramer, Kim
    Kundranda, Madappa N.
    Alvarez, Ricardo H.
    Klimant, Eiko
    Parikh, Ankur R.
    Tan, Bradford
    Staren, Edgar D.
    Markman, Maurie
    ONCOTARGETS AND THERAPY, 2015, 8 : 3323 - 3328
  • [49] ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
    Reinert, Tomas
    Ramalho, Susana
    Antunes de Vasconcelos, Vivian Castro
    Silva, Leonardo Roberto
    Ribeiro da Silva, Ana Elisa
    de Andrade, Camila Annicchino
    de Paula Leite Kraft, Maria Beatriz
    Coelho, Guilherme Portela
    Mandelli, Jovana
    Binotto, Monique
    Cabello, Cesar
    de Paiva Silva, Geisilene Russano
    Bines, Jose
    Barrios, Carlos H.
    Ellis, Matthew J.
    Graudenz, Marcia Silveira
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] The incidence and clinical significance of ESR1 mutations in patients with heavily pretreated metastatic breast cancer
    Niu, J.
    Andres, G.
    Kramer, K.
    Kundranda, M.
    Weiss, G.
    Klimant, E.
    Parikh, A.
    Tan, B.
    Staren, E.
    Markman, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S294 - S294
12345